ZFP92 Inhibitors
ZFP92 inhibitors encompass a range of chemical entities that, through their distinct biochemical mechanisms, indirectly reduce the functional activity of ZFP92, a zinc finger protein involved in gene regulation. Certain inhibitors work by altering the epigenetic landscape, such as compounds that inhibit histone deacetylases and DNA methyltransferases, leading to changes in the chromatin structure and DNA methylation patterns, respectively. These changes can affect the expression and function of ZFP92 by modifying the accessibility of transcription factors and the gene regulatory network. Another approach involves the modulation of protein degradation pathways, where proteasome inhibitors can increase the cellular concentration of ubiquitinated proteins, thus potentially influencing the degradation pathways of ZFP92 and its regulatory proteins, resulting in an indirect inhibition of ZFP92's activity.
Additional inhibitors target key signaling molecules and pathways that regulate gene expression and protein synthesis, which can have downstream effects on ZFP92. Inhibitors of cyclin-dependent kinases,mTOR, PI3K, MEK, and p38 MAP kinase are examples of compounds that disrupt the normal signaling cascades within the cell, leading to an altered regulation of ZFP92. For instance, by interfering with the PI3K-Akt pathway, downstream signaling events that may regulate ZFP92 are affected, potentially altering its function. The use of MEK inhibitors, which act upstream of ERK, can also alter the ERK-mediated signaling events and subsequently the regulation of genes including those governing the activity of ZFP92. Furthermore, the disruption of calcium homeostasis through the inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase can influence numerous cellular processes, including those that regulate ZFP92, thereby contributing to the inhibition of its functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This hydroxamic acid derivative acts as an inhibitor of histone deacetylases (HDACs). By preventing deacetylation, it leads to a hyperacetylated state of histones, which can alter gene expression patterns including those of ZFP92 by affecting the chromatin structure and its accessibility to the transcription machinery. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a DNA methyltransferase inhibitor, this compound incorporates into DNA and RNA, leading to hypomethylation of DNA. Hypomethylated DNA may result in the upregulation or downregulation of different genes, which can indirectly affect the expression and function of ZFP92 by disrupting its gene regulatory network. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
This peptide aldehyde is a potent proteasome inhibitor which can lead to an increased cellular concentration of ubiquitinated proteins, potentially influencing the degradation pathways of proteins including ZFP92, indirectly leading to its inhibition. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
This compound is a cyclin-dependent kinase inhibitor, which can interfere with cell cycle progression. By affecting these kinases, it can indirectly influence the regulation of ZFP92 through cell cycle-dependent pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This morpholine derivative acts as a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3Ks, it disrupts downstream signaling pathways that can influence the function and regulation of ZFP92. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As a specific inhibitor of mTOR, this macrolide compound can disrupt the mTOR signaling pathway, which has broad effects on cellular processes including protein synthesis and degradation, potentially affecting the functional activity of ZFP92 indirectly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This pyridinyl imidazole derivative selectively inhibits p38 MAP kinase. The inhibition of p38 MAPK can lead to altered transcriptional regulation, potentially impacting the expression levels and activity of ZFP92. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This compound is a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. Inhibiting MEK activity can indirectly affect the function of ZFP92 by altering the ERK-mediated signaling events that regulate gene expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A boronic acid dipeptide, this compound inhibits the 26S proteasome, affecting the degradation of ubiquitinated proteins, which may lead to the dysregulation of proteins such as ZFP92 through the accumulation of regulatory proteins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
By inhibiting MEK, which acts upstream of ERK, this compound can modulate ERK pathway signaling. The disruption of this pathway can lead to changes in the regulation of gene expression that affect the activity of ZFP92. | ||||||